U.K. Rare Diseases Framework, a government-led approach to raising national awareness of rare disorders, accelerating diagnoses, and improving patient…
Articles by Joana Carvalho, PhD
Triplet Therapeutics announced it has completed patient enrollment in SHIELD HD, a natural history study documenting the course of…
No significant safety concerns associated with AMT-130, uniQure’s experimental gene therapy for Huntington’s disease, were identified in the…
An enzyme called TANK‐binding kinase 1 (TBK1) can lower levels of the mutant huntingtin protein — which underlies the…
The length of CAG repeats within the huntingtin (HTT) gene tends to increase as people with Huntington’s disease…
Mutations associated with Huntington’s disease increase nerve cells’ resistance to high levels of manganese, according to a…
Different types of apathy — a common psychiatric symptom of Huntington’s disease — are associated with specific alterations…
Laquinimod, an experimental immunomodulatory therapy developed by Active Biotech and Teva Pharmaceuticals, reduced signs of inflammation and…
Huntington’s disease may manifest itself for the first time during neurulation, a process in which the neural…
Patients at a pre-symptomatic stage of Huntington’s disease have marked difficulties recognizing and understanding negative and neutral mental…